科兴生物制药股份有限公司申请版本

Application Proof of Kexing Biopharm Co., Ltd. (A joint stock company incorporated in the People’s Republic of China with limited liability) WARNING Thepublication of this Application Proof is required by The Stock Exchange of Hong Kong Limited(the“Exchange”) and the Securities and Futures Commission (the “Commission”) solely for the purpose of providinginformation to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is subject to change whichcan be material. By viewing this document, you acknowledge, accept and agree with Kexing Biopharm Co., Ltd. (the“Company”), its sponsor, overall coordinator, advisors or member of the underwriting syndicate that: (i)this document is only for the purpose of providing information about the Company to the public in Hong Kongand not for any other purposes. No investment decision should be based on the information contained in thisdocument;(ii)the publication of this document or supplemental, revised or replacement pages on the Exchange’s websitedoes not give rise to any obligation of the Company, its sponsor, overall coordinator, advisors or member ofthe underwriting syndicate to proceed with an offering in Hong Kong or any other jurisdiction. There is noassurance that the Company will proceed with the offering;(iii)the contents of this document or supplemental, revised or replacement pages may or may not be replicated infull or in part in the actual final listing document;(iv)the Application Proof is not the final listing document and may be updated or revised by the Company fromtime to time in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of HongKong Limited;(v)this document does not constitute a prospectus, offering circular, notice, circular, brochure or advertisementoffering to sell any securities to the public in any jurisdiction, nor is it an invitation to the public to make offersto subscribe for or purchase any securities, nor is it calculated to invite offers by the public to subscribe foror purchase any securities;(vi)this document must not be regarded as an inducement to subscribe for or purchase any securities, and no suchinducement is intended;(vii)neither the Company nor any of its affiliates, advisors or underwriters is offering, or is soliciting offers to buy,any securities in any jurisdiction through the publication of this document;(viii)no application for the securities mentioned in this document should be made by any person nor would suchapplication be accepted;(ix)the Company has not and will not register the securities referred to in this document under the United StatesSecurities Act of 1933, as amended, or any state securities laws of the United States;(x)as there may be legal restrictions on the distribution of this document or dissemination of any informationcontained in this document, you agree to inform yourself about and observe any such restrictions applicableto you; and(xi)the application to which this document relates has not been approved for listing and the Exchange and theCommission may accept, return or reject the application for the subject public offering and/or listing. If an offer or an invitation is made to the public in Hong Kong in due course, prospective investors are reminded tomaketheir investment decisions solely based on the Company’s prospectus registered with the Registrar ofCompanies in Hong Kong, copies of which will be published to the public during the offer period. IMPORTANT If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. Kexing Biopharm Co., Ltd. (A joint stock company incorporated in the People’s Republic of China with limited liability) [REDACTED] Number of[REDACTED]underthe[REDACTED]:[REDACTED]H Shares (subject tothe[REDACTED])Number of[REDACTED]:[REDACTED]H Shares (subject to[REDACTED])Number of[REDACTED]:[REDACTED]H Shares (subject to[REDACTED]and the[REDACTED])Maximum[REDACTED]:HK$[REDACTED]per[REDACTED],plus brokerage of 1%, Stock Exchangetrading fee of 0.00565%, SFCtransaction levy of 0.0027% andAFRC transaction levy of 0.00015%(payable in full on application in HongKong dollars and subject to refund)Nominal value:RMB[REDACTED]per H ShareStock code:[REDACTED] Sole Sponsor, Sole Sponsor-Overall Coordinator, Sole Overall Coordinator,[REDACTED],[REDACTED]and[REDACTED] Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibilityfor the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoeverarising from or in reliance upon the whole or any part of the contents of this document. A copy of this document, having attached thereto the documents specified in “Documents Delivered to the Registrar of Companies and Available on Display —Document